To the full analysis
Buyback calculator for Rigel Pharmaceuticals
Rigel Pharmaceuticals stock: key metrics
RIGLRigel Pharmaceuticals had an operating margin of 42.6% and a return on invested capital (ROIC) of 91% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 100.0% | −128.6% | −112.4% |
| 2007 | 100.0% | −631.2% | −589.5% |
| 2008 | no data | no data | no data |
| 2009 | −87.1% | −14,938.3% | −14,872.9% |
| 2010 | 100.0% | 28.3% | 30.3% |
| 2011 | 100.0% | −1,818.3% | −1,810.0% |
| 2012 | −3,401.2% | −4,416.8% | −4,392.9% |
| 2013 | −953.5% | −1,251.3% | −1,245.1% |
| 2014 | −720.6% | −1,106.0% | −1,101.9% |
| 2015 | −117.4% | −179.1% | −178.1% |
| 2016 | −211.3% | −342.2% | −339.6% |
| 2017 | −931.9% | −1,775.6% | −1,739.3% |
| 2018 | 99.4% | −163.3% | −158.3% |
| 2019 | 98.5% | −116.5% | −112.2% |
| 2020 | 99.2% | −26.7% | −27.4% |
| 2021 | 99.3% | −8.4% | −12.0% |
| 2022 | 98.5% | −46.2% | −48.7% |
| 2023 | 93.9% | −17.5% | −21.5% |
| 2024 | 89.6% | 13.5% | 9.8% |
| 2025 | 93.3% | 42.6% | 124.7% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −43.1% | −32.9% | −33.2% |
| 2007 | −90.4% | −61.6% | −64.1% |
| 2008 | −100.0% | −97.4% | −92.0% |
| 2009 | −100.0% | −72.5% | −79.3% |
| 2010 | 22.8% | 23.6% | 20.3% |
| 2011 | −36.4% | −32.4% | −33.4% |
| 2012 | −34.2% | −28.9% | −31.9% |
| 2013 | −42.7% | −27.5% | −39.4% |
| 2014 | −70.9% | −40.5% | −59.0% |
| 2015 | −56.3% | −34.3% | −39.1% |
| 2016 | −100.0% | −71.8% | −88.6% |
| 2017 | −77.5% | −80.5% | −65.5% |
| 2018 | −64.1% | −54.1% | −50.7% |
| 2019 | −100.0% | −54.4% | −45.1% |
| 2020 | −87.4% | −28.8% | −26.9% |
| 2021 | −59.0% | −11.4% | −10.7% |
| 2022 | 200.0% | −50.8% | −43.6% |
| 2023 | 87.6% | −23.1% | −21.4% |
| 2024 | 200.0% | 25.7% | 10.7% |
| 2025 | 93.8% | 91.0% | 71.5% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 10 Nov 2026, previously Neutral
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.